(Q42984235)

12 November 2017

title

Primary immunisation of hepatitis C virus (HCV)-specific antibody producing B cells by lipidated peptides (English)

1 reference

12 November 2017

1 reference

Bettina Langhans

1

1 reference

12 November 2017

Ingrid Braunschweiger

2

1 reference

12 November 2017

Susann Schweitzer

3

1 reference

12 November 2017

Tilman Sauerbruch

4

1 reference

12 November 2017

Ulrich Spengler

5

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

12 November 2017

1 reference

12 November 2017

volume

22

1 reference

12 November 2017

issue

11-12

1 reference

12 November 2017

page(s)

1441-1447

1 reference

Lipopeptide vaccines--yesterday, today, and tomorrow

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Extension of HLA-A*0201-restricted minimal epitope by N epsilon-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)--core protein is mediated by toll like receptors (TLRs) 2 and 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope‐specific B‐, T‐helper and T‐killer cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Induction of antigen-specific isotype switching by in vitro immunization of human naive B lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

New therapeutic strategies for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Strategy for the production of human monoclonal antibodies using in vitro activated B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Flow cytometric analysis of peptide binding to major histocampatibility complex class I for hepatitis C virus core T-cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Lipidation of T helper sequences from hepatitis C virus core significantly enhances T-cell activity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

In vitro sensitization for human monoclonal antibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.014

10.1016/J.VACCINE.2003.10.014

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference